On October 2, Sanofi SA fell 3.15% in pre-market trading, trading at $39.39/share, with turnover of $972,200. The pullback follows a 9.4% surge in the prior session, when the company issued optimistic fiscal year revenue and profit guidance that was projected to exceed market expectations, triggering short-term profit-taking.

Adding to the pressure, market attention has focused on the freshly expanded collaboration between Sanofi and Regeneron. On October 1, the two companies announced an expanded immunology partnership worth up to $8 billion, under which Sanofi will pay a $1 billion upfront fee and up to $7 billion in milestone payments to co-develop four novel long-acting antibodies targeting IL-13, IL-4, IL-4R, and IL-4/IL-13. RBC Capital Markets noted that Regeneron needs to secure better economic terms on follow-on products beyond Dupixent, and the uncertainty surrounding the final structure of the deal has weighed on sentiment.

Meanwhile, Sanofi previously terminated clinical development of amlitelimab for moderate-to-severe atopic dermatitis after concluding that accumulated data did not support further progress, adding pipeline risk concerns for investors ahead of the next earnings report expected on October 30.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)